Making The Most Of A Renaissance Moment In Health Care

The Many Good Things To Emerge From The Havoc Wrought By COVID Must Not Be Squandered

The rise of digital alongside long-established physical methods of care delivery should not give rise to notions of an "either/or" choice, but should rather be seen as an “and,” said Accenture’s Andrew Meade in conversation with In Vivo.

Alamy

The worst thing that could happen post-COVID-19 is that the signals the pandemic gave and improvement possibilities it flagged up are not integrated sustainably into health care practice on national and global levels.

That is the view of Andrew Meade, managing director and life sciences lead, UKI, for consulting and professional services group...

More from Business Strategy

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.